Invention for Natural killer cells are used to treat hematological disorders or solid tumors.

Invented by Lin Kang, Xiaokui Zhang, Jeffrey Harris, Vladimir Jankovic, Celgene Corp

The Market for Natural Killer Cells Used to Treat Hematological Disorders or Solid Tumors Natural Killer (NK) cells are a type of immune cell that play a crucial role in the body’s defense against cancer and other diseases. These cells have the ability to recognize and eliminate abnormal cells, including cancer cells, without prior sensitization or the need for specific antigens. This unique characteristic has made NK cells a promising therapeutic option for the treatment of hematological disorders and solid tumors. The market for NK cell therapy has been steadily growing in recent years, driven by advancements in cell-based immunotherapies and the increasing prevalence of cancer worldwide. According to a report by Grand View Research, the global NK cell therapy market size was valued at $1.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 46.1% from 2021 to 2028. Hematological disorders, such as leukemia, lymphoma, and multiple myeloma, are among the primary targets for NK cell therapy. These disorders affect the blood and bone marrow, and traditional treatment options like chemotherapy and radiation therapy often have limited efficacy or significant side effects. NK cell therapy offers a promising alternative by harnessing the body’s own immune system to specifically target and eliminate cancer cells. In the case of solid tumors, NK cell therapy faces additional challenges due to the complex tumor microenvironment and the ability of cancer cells to evade immune detection. However, researchers and biotech companies have been working on developing innovative strategies to overcome these obstacles. For instance, genetic engineering techniques can be used to enhance the anti-tumor activity of NK cells by introducing specific receptors or modifying their surface proteins. The market for NK cell therapy is highly competitive, with several companies actively involved in research and development, clinical trials, and commercialization efforts. Some of the key players in this market include Fate Therapeutics, Nkarta Therapeutics, Kiadis Pharma, and CytoSen Therapeutics. These companies are not only focused on developing NK cell therapies for hematological disorders and solid tumors but also exploring their potential in other areas, such as viral infections and autoimmune diseases. Despite the significant progress made in the field of NK cell therapy, there are still challenges that need to be addressed for its widespread adoption. One of the major hurdles is the scalability and manufacturing of NK cells in large quantities. The production of clinical-grade NK cells requires specialized facilities and expertise, which can limit their availability and increase the cost of therapy. Efforts are underway to optimize manufacturing processes and develop off-the-shelf NK cell products that can be readily available for patients. Another challenge is the regulatory landscape surrounding cell-based therapies. As NK cell therapy is a relatively new and rapidly evolving field, there is a need for clear guidelines and regulations to ensure patient safety and facilitate the development and commercialization of these therapies. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are actively working on establishing frameworks for the approval and regulation of cell-based therapies. In conclusion, the market for NK cells used to treat hematological disorders or solid tumors is witnessing significant growth and innovation. With ongoing research, advancements in manufacturing techniques, and regulatory support, NK cell therapy has the potential to revolutionize cancer treatment and improve patient outcomes. As the field continues to evolve, it is crucial to foster collaboration between academia, industry, and regulatory bodies to accelerate the development and adoption of this promising therapeutic approach.

The Celgene Corp invention works as follows

The invention provides methods for treating a hematological disease, a solid tumour, or an infectious illness in a patient in need of such treatment using natural killer cell in combination with another agent or by using natural killer cell with genetic modification to increase target specificity or homing specificity.

Background for Natural killer cells are used to treat hematological disorders or solid tumors.

3.1. Terminology

4. “4.

5.1. “5.1.

5.1.1. Placental Intermediate Natural Killer (PiNK) Cells

5.1.2. Activated NK Cells

5.1.3. “5.1.3. TSPNK Cells “

5.1.4. “5.1.4.

5.1.5. “5.1.5. “ Combination of NK cells from matched perfusate cord blood and matched perfusate Combinations of NK cells with adherent placental stem cells “ Compositions containing adherent placental cell conditioned media

5.2. “5.2.

5.2.1. “5.2.1.

5.2.2. “5.2.2.

5.2.3. “5.2.3.

5.2.4. “5.2.4.

5.2.5. Hematopoietic cells “

Click here to view the patent on Google Patents.